Related references
Note: Only part of the references are listed.Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group
R. Dreicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Molecular Pathogenesis and Diagnostics of Bladder Cancer
Anirban P. Mitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer
Tibor Szarvas et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases
Donna E. Hansel et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
William E. Osai et al.
ANTI-CANCER DRUGS (2008)
The endothelin axis in cancer:: the promise and the challenges of molecularly targeted therapy
Anna Bagnato et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2008)
Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
Joel B. Nelson et al.
CANCER (2008)
Sensitivity to epidermal growth factor receptor inhibitor requires E-cedherin expression in urothelial carcinoma cells
Peter C. Black et al.
CLINICAL CANCER RESEARCH (2008)
Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
Mel Wu et al.
CLINICAL THERAPEUTICS (2008)
Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors
Margaret A. Knowles
FUTURE ONCOLOGY (2008)
Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy patients with advanced or metastatic non-small-cell lung cancer (vol 25, pg 5777, 2007)
Butts
JOURNAL OF CLINICAL ONCOLOGY (2008)
Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
D. J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Wassim Kassouf et al.
JOURNAL OF UROLOGY (2008)
Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
Jorge L. Martinez-Torrecuadrada et al.
MOLECULAR CANCER THERAPEUTICS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas
Vildan Caner et al.
PATHOLOGY & ONCOLOGY RESEARCH (2008)
Growth factors and receptors as prognostic markers in urothelial carcinoma
Peter C. Black et al.
Current Urology Reports (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib
Micah A. Jacobs et al.
JOURNAL OF UROLOGY (2007)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
D. C. Tomlinson et al.
ONCOGENE (2007)
Angiopoietin: A TIE(d) balance in tumor angiogenesis
Winston S. N. Shim et al.
MOLECULAR CANCER RESEARCH (2007)
A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
Richard Kefford et al.
INVESTIGATIONAL NEW DRUGS (2007)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha
Jia-Lin Yang et al.
BJU INTERNATIONAL (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification
Anirban P. Mitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel
Khalid A. Mohamedali et al.
CANCER RESEARCH (2006)
Trastuzumab (Herceptin®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder:: report on 7 patients
Marc Salzberg et al.
EUROPEAN JOURNAL OF CANCER (2006)
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy
Kelly N. Blehm et al.
CLINICAL CANCER RESEARCH (2006)
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas
Silvia Hernandez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
Christopher J. Sweeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo
Joji Nagasawa et al.
INTERNATIONAL JOURNAL OF UROLOGY (2006)
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer
GB Xia et al.
JOURNAL OF UROLOGY (2006)
FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer
P Mhawrech-Fauceglia et al.
EJSO (2006)
Trastuzumab (Herceptin™) in metastatic transitional cell carcinoma of the urinary tract:: Report on six patients
M Peyromaure et al.
EUROPEAN UROLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors
KA Mohamedali et al.
NEOPLASIA (2005)
Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain FvAntibodies inhibits bladder carcinoma cell line proliferation
JM Martínez-Torrecuadrada et al.
CLINICAL CANCER RESEARCH (2005)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of the endothelin axis in bladder cancer:: Relationship to clinicopathologic parameters and long-term survival
C Wülfing et al.
EUROPEAN UROLOGY (2005)
The vascular-ablative agent VEGF121/rGel inhibits pulmonary Metastases of MDA-MB-231 breast tumors
S Ran et al.
NEOPLASIA (2005)
Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erbb-2) status in urothelial carcinoma
G de Pinieux et al.
VIRCHOWS ARCHIV (2004)
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group
R Dreicer et al.
CANCER (2004)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression
A Bagnato et al.
CANCER RESEARCH (2004)
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts
DW Davis et al.
CANCER RESEARCH (2004)
HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Z Latif et al.
EUROPEAN JOURNAL OF CANCER (2004)
The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression
CC Yang et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2004)
Epidermal growth factor receptor biology (IMC-C225)
ES Kim et al.
CURRENT OPINION IN ONCOLOGY (2001)
Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer
S Bernardini et al.
JOURNAL OF UROLOGY (2001)
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
M Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
D Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
